Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|April 16, 2018
Clinical Approach for Unresectable Locally Advanced NSCLC
Clinical Approach for Unresectable Locally Advanced NSCLC
Advertisement
- A 63-year-old man presented to his PCP with intermittent cough and difficulty breathing on exertion
- PMH: hyperlipidemia well-managed on simvastatin; hypothyroidism, managed on levothyroxine, COPD on inhalers
- Recently quit smoking; has a 40-pack-year history
- PE; intermittent wheezing; ECOG 1
- Creatinine clearance, WNL
- Imaging Studies:
- Chest X-ray showed opacity in the lung right upper lobe
- Chest CT revealed a 3.1-cm spiculated mass in the right upper lobe and 2 enlarged right mediastinal lymph nodes measuring 1.5 cm and 1.7 cm; moderate emphysema noted
- PET confirmed the lung lesion and mediastinal lymphadenopathy without evidence of distant metastasis
- Brain MRI was negative
- Bronchoscopy with transbronchial lung biopsy and lymph node sampling revealed adenocarcinoma with positive nodes in stations 4R and 7; level 4L was negative
- Genetic testing was negative for known driver mutations
- Staging: T2aN2M0, stage IIIA
- Based on the extent of mediastinal disease and emphysema, the patient’s cancer was deemed inoperable, and he was referred for consideration of concurrent chemotherapy and radiation
- He underwent therapy with cisplatin/etoposide and concurrent thoracic radiotherapy
- Follow-up imaging showed a partial response with shrinkage of the primary and nodal lesions
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5